Date: 2013-01-07
Type of information: Licensing agreement
Compound: companion diagnostic
Company: Qiagen (The Netherlands) Drug Response Dx (Germany)
Therapeutic area: Autoimmune diseases – Inflammatory diseases - Rheumatic diseases
Type agreement: equity investment
licensing option
Action mechanism:
Disease: rheumatoid arthritis
Details: * On January 7, 2013, Qiagen has announced three separate agreements that add new biomarkers to its pipeline of personalized healthcare diagnostics. The first one has been concluded with a young German company, Drug Response Dx. Qiagen has made a strategic equity investment the company with the option to obtain worldwide rights to biomarkers for evaluation of rheumatoid arthritis (RA) patients to guide treatment with TNF-alpha inhibitors. This companion diagnostic to predict which RA patients are likely to respond to TNF-alpha inhibitors would be highly complementary in the RA marketplace with QuantiFERON-TB Gold, Qiagen’s gold standard test for detection of latent tuberculosis (TB), since the prescribing information for many TNF-alpha inhibitors and other biological medicines requires testing for latent TB before use of the medicines.
Financial terms:
Latest news:
